Caris Life Sciences has launched a new national awareness campaign featuring actor, director and producer Kevin Costner as the company looks to bring greater public attention to the importance of finding cancer at an earlier stage. The campaign, titled “Math,” introduces audiences to Caris Detect, the company’s multi-cancer early detection blood test, as the company expands its efforts in the growing field of molecular cancer testing.
The campaign centers on a straightforward message: detecting cancer earlier can give patients more opportunities to consider treatment and may improve outcomes. Through its partnership with Costner, Caris is taking that message beyond the clinical setting and into mainstream consumer awareness, targeting people who may not otherwise be familiar with emerging blood-based approaches to cancer detection.
The campaign arrives as the cancer diagnostics industry continues to expand beyond conventional screening and diagnostic methods. Advances in molecular testing are giving companies new ways to examine biological signals associated with cancer, including signals that may emerge before a person develops noticeable symptoms. Caris Detect is designed to complement routine cancer screening by examining molecular information circulating in the blood.
Caris Detect Uses Broad Molecular Analysis for Early Cancer Signals
Caris Detect is designed as a multi-cancer early detection test that looks for molecular signals associated with cancer through a blood sample. Rather than focusing on a narrow group of biomarkers, the test uses ultra-deep Whole Genome Sequencing and Whole Transcriptome Sequencing to examine a broad range of genetic and biological information.
The approach allows the company to analyze both the genome and transcriptome, providing a wider molecular picture of potential cancer-associated changes. Caris also incorporates advanced computational analysis into the testing process to evaluate these signals and identify patterns that may be associated with cancer.
For the healthcare industry, the development of multi-cancer tests represents an important area of interest because conventional cancer screening is often organized around individual cancer types. A blood test capable of detecting signals associated with multiple cancers could potentially provide another avenue for identifying disease and prompting further clinical evaluation.
Caris is positioning its test as an additional source of information rather than a replacement for established screening programs. The company says Caris Detect is intended to complement routine cancer screening and support conversations between individuals and healthcare professionals.
The availability of the test nationwide also gives Caris an opportunity to expand its presence in the consumer-facing side of cancer testing. As awareness of molecular diagnostics grows, companies operating in this space are increasingly focused not only on laboratory capabilities but also on explaining complex technologies to the general public.
That communication challenge is central to the “Math” campaign. Instead of leading with technical details, the campaign focuses on the potential value of earlier information and the decisions that may follow from it.
David Dean Halbert, founder, chairman and chief executive officer of Caris Life Sciences, said early detection remains a significant opportunity in cancer care. He pointed to the company’s experience in molecular science and advanced computational methods as part of its effort to develop technologies that could identify cancer earlier.
Kevin Costner Partnership Broadens Public Reach of Cancer Testing
Costner’s involvement gives the campaign a prominent public figure who can communicate the early detection message to a broad audience. Caris said the actor was drawn to the partnership because of the company’s focus on providing people with information that could support earlier healthcare decisions.
Cancer has affected families across the world, making early detection a subject with broad public relevance. By placing the message within a national advertising campaign, Caris is seeking to make conversations about cancer testing more familiar outside hospitals, laboratories and physician offices.
The commercial also reflects a larger shift in the diagnostics business. As new molecular testing platforms reach the market, companies are increasingly competing on their ability to combine scientific development with accessibility and public awareness. For providers, patients and healthcare organizations, the value of these tests depends not only on laboratory performance but also on whether people understand when and why they may be appropriate.
Caris has built its business around molecular profiling and the use of genomic information in precision medicine. Its technology portfolio includes Whole Genome, Whole Exome and Whole Transcriptome Sequencing, supported by a large clinical and genomic data infrastructure.
The company is applying these capabilities across several areas of healthcare, including early detection, diagnosis, disease monitoring, treatment selection and drug development. Caris Detect adds another commercial application to that broader platform by focusing specifically on identifying cancer-associated signals before conventional symptoms may become apparent.
The company’s expansion into multi-cancer early detection comes as the diagnostics industry continues to examine how blood-based testing could change cancer screening and monitoring. The commercial opportunity is potentially significant, but the sector also faces the challenge of ensuring that emerging tests are appropriately understood and incorporated into clinical care.
For Caris, the Kevin Costner campaign provides a way to address that challenge while building recognition for its testing platform. The campaign’s message is aimed at encouraging people to become more proactive about their health and discuss available testing options with healthcare professionals.
Caris Detect is now available nationwide, according to the company. Individuals can learn more about the test through Caris’ dedicated consumer information platform.
The launch gives Caris a stronger public presence in the early cancer detection market while highlighting the company’s broader strategy of combining molecular testing with data-driven healthcare applications. As cancer diagnostics continues to develop, greater access to information and earlier identification of potential disease could become increasingly important elements of how patients and physicians approach cancer care.
